Kim Christopher
SEC CIK 2040022 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| APUS | Apimeds Pharmaceuticals US, Inc. | COB, CMO, Dir | 277.5K | $50.4K | — | 2 | 2025-05-13 | 2025-05-16 |
Most active insiders at APUS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| No open-market trades in the last year. | ||||
Kim Christopher made no open-market trades at APUS in the last 12 months.
Transactions 2
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-20 | 2025-05-16 | APUS | Apimeds Pharmaceuticals US, Inc. | Kim Christopher | COB, CMO, Dir | A - Grant | $0.00 | +250.0K | 277.5K | +909% | $0 | |
| M | 2025-05-15 | 2025-05-13+ | APUS | Apimeds Pharmaceuticals US, Inc. | Kim Christopher | COB, CMO, Dir | P - Purchase | $1.83 | +27.5K | 19.8K | New | +$50.4K |
Purchase Sale Sale after option exercise All abbreviations